{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T05:57:21Z","timestamp":1790575041495,"version":"4.1.0"},"reference-count":18,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Small intestinal bacterial overgrowth (SIBO) is a disorder associated with gastrointestinal symptoms, alterations in gut microbiota composition, and a high rate of recurrence. Although antibiotic therapy remains the cornerstone of treatment, dietary interventions are increasingly used as adjunctive strategies to improve symptom control and support long-term management. However, international recommendations regarding dietary management remain heterogeneous and lack standardization. Therefore, the aim of this systematic review was to analyze and compare dietary recommendations for the treatment of SIBO presented by international scientific organizations and recent expert reviews.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This guidelines review was conducted in accordance with PRISMA 2020 recommendations. PubMed and Cochrane Library were searched for publications published between January 2016 and January 2026. Eligible documents included clinical guidelines, consensus statements, official position papers, and supplementary expert review articles addressing dietary management in SIBO. Data were extracted on the role of dietary therapy, low-FODMAP recommendations, dietary fiber, probiotics, prebiotics, treatment priorities, and the reported impact of dietary interventions on the gut microbiota. A qualitative synthesis of recommendations from different geographic regions was performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Five key documents from North America, South America, Europe, and the Asia-Pacific region met the inclusion criteria. Dietary therapy was consistently regarded as supportive rather than curative, although its perceived importance varied across regions. The low-FODMAP diet was the most frequently discussed dietary intervention and was generally recommended for symptom relief, particularly for bloating, abdominal pain, and altered bowel habits. Nevertheless, evidence supporting its role in eradicating SIBO remains insufficient. Recommendations regarding dietary fiber, probiotics, and prebiotics were heterogeneous and largely emphasized individualized use. Antibiotic therapy and management of underlying predisposing factors remained the central therapeutic strategy in all analyzed regions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Despite increasing interest in nutritional approaches, substantial international variability exists in dietary recommendations for SIBO. Current evidence supports dietary therapy primarily as an adjunct to medical treatment and a tool for symptom management. High-quality prospective studies are needed to establish standardized, evidence-based dietary recommendations and to clarify the long-term effects of dietary interventions on the gut microbiota and disease recurrence.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1952995","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T05:45:26Z","timestamp":1790574326000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Global perspectives on dietary management of small intestinal bacterial overgrowth (SIBO): a systematic review of clinical guidelines, consensus statements and expert recommendations"],"prefix":"10.3389","volume":"13","author":[{"given":"Magdalena","family":"Jodkiewicz","sequence":"first","affiliation":[{"name":"Medical Center of Dietetics and Health Education, National Institute of Public Health NIH - National Research Institute","place":["Warsaw, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justyna","family":"Malinowska","sequence":"additional","affiliation":[{"name":"Medical Center of Dietetics and Health Education, National Institute of Public Health NIH - National Research Institute","place":["Warsaw, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolina","family":"Marek-Wo\u017any","sequence":"additional","affiliation":[{"name":"Medical Center of Dietetics and Health Education, National Institute of Public Health NIH - National Research Institute","place":["Warsaw, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1053\/j.gastro.2026.02.003","article-title":"Bowel disorders","volume":"170","author":"Corsetti","year":"2026","journal-title":"Gastroenterology"},{"key":"B2","doi-asserted-by":"publisher","first-page":"3400","DOI":"10.3748\/wjg.v29.i22.3400","article-title":"Epidemiology of small intestinal bacterial overgrowth","volume":"29","author":"Efremova","year":"2023","journal-title":"World J Gastroenterol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1136\/flgastro-2022-102163","article-title":"Aetiology, diagnosis and management of small intestinal bacterial overgrowth","volume":"14","author":"Ahmed","year":"2023","journal-title":"Frontline Gastroenterol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"3382","DOI":"10.3390\/nu14163382","article-title":"Efficacy of an irritable bowel syndrome diet in the treatment of small intestinal bacterial overgrowth: a narrative review","volume":"14","author":"Wielgosz-Grochowska","year":"2022","journal-title":"Nutrients"},{"key":"B5","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/j.cgh.2008.02.058","article-title":"Dietary triggers of abdominal symptoms in patients with irritable bowel syndrome: randomized placebo-controlled evidence","volume":"6","author":"Shepherd","year":"2008","journal-title":"Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc"},{"key":"B6","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1017\/S0029665123003579","article-title":"The low FODMAP diet in clinical practice: where are we and what are the long-term considerations?","volume":"83","author":"Lomer","year":"2024","journal-title":"Proc Nutr Soc"},{"key":"B7","doi-asserted-by":"publisher","first-page":"3505","DOI":"10.1007\/s00394-020-02473-0","article-title":"Efficacy of a low-FODMAP diet in adult irritable bowel syndrome: a systematic review and meta-analysis","volume":"60","author":"Van Lanen","year":"2021","journal-title":"Eur J Nutr"},{"key":"B8","doi-asserted-by":"publisher","first-page":"165","DOI":"10.14309\/ajg.0000000000000501","article-title":"ACG clinical guideline: small intestinal bacterial overgrowth","volume":"115","author":"Pimentel","year":"2020","journal-title":"Off J Am Coll Gastroenterol ACG"},{"key":"B9","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s12664-022-01292-x","article-title":"Asian-Pacific consensus on small intestinal bacterial overgrowth in gastrointestinal disorders: an initiative of the Indian neurogastroenterology and motility association","volume":"41","author":"Ghoshal","year":"2022","journal-title":"Indian J Gastroenterol Off J Indian Soc Gastroenterol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e24107","DOI":"10.1590\/S0004-2803.24612024-107","article-title":"Diagnosis and treatment of small intestinal bacterial overgrowth: an official position paper from the Brazilian federation of gastroenterology","volume":"62","author":"Silva","year":"2025","journal-title":"Arq Gastroenterol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.3390\/nu16071083","article-title":"Do herbal supplements and probiotics complement antibiotics and diet in the management of SIBO? A randomized clinical trial","volume":"16","author":"Redondo-Cuevas","year":"2024","journal-title":"Nutrients"},{"key":"B12","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.rgmxen.2024.08.003","article-title":"Treatment of small intestinal bacterial overgrowth in Chilean patients with irritable bowel syndrome: a prospective and comparative study","volume":"90","author":"Von Muhlenbrock","year":"2025","journal-title":"Rev Gastroenterol Mex"},{"key":"B13","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/apt.70420","article-title":"Clinical trial: rifaximin versus low FODMAP diet in irritable bowel syndrome","volume":"63","author":"Chuah","year":"2026","journal-title":"Aliment Pharmacol Ther"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1725524","DOI":"10.3389\/fnut.2026.1725524","article-title":"Effectiveness of the low FODMAP diet in patients with irritable bowel syndrome and small intestine bacterial overgrowth syndrome","volume":"13","author":"Bogdanowska-Charkiewicz","year":"2026","journal-title":"Front Nutr"},{"key":"B15","doi-asserted-by":"publisher","first-page":"046007","DOI":"10.1088\/1752-7163\/ae0aec","article-title":"Therapeutic effect of the low FODMAPs diet for refractory halitosis associated with small intestinal bacterial overgrowth","volume":"19","author":"Gong","year":"2025","journal-title":"J Breath Res"},{"key":"B16","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1097\/MPG.0000000000003526","article-title":"An ESPGHAN position paper on the use of low-FODMAP diet in pediatric gastroenterology","volume":"75","author":"Thomassen","year":"2022","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"B17","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1093\/ajcn\/nqac176","article-title":"Effects of a low FODMAP diet on the colonic microbiome in irritable bowel syndrome: a systematic review with meta-analysis","volume":"116","author":"So","year":"2022","journal-title":"Am J Clin Nutr"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1111\/j.1365-2036.2010.04436.x","article-title":"Clinical trial: the combination of rifaximin with partially hydrolysed guar gum is more effective than rifaximin alone in eradicating small intestinal bacterial overgrowth","volume":"32","author":"Furnari","year":"2010","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1952995\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T05:45:27Z","timestamp":1790574327000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1952995\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":18,"alternative-id":["10.3389\/fmed.2026.1952995"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1952995","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,28]]},"article-number":"1952995"}}